JPMorgan Funds - Global Healthcare Fund A (acc) - EUR
JPMorgan Funds (SICAV domiciled in Luxembourg)
Key Information
Legal Documents
Performance
Analysis

Fund Profile

Category: SICAV

To achieve a return by investing primarily in pharmaceutical, biotechnology, healthcare services, medical technology and life sciences companies ("Healthcare Companies"), globally. Investment approach B Uses a research-driven investment process that is based on the fundamental analysis of companies and their future earnings and cash flows by a team of specialist sector analysts. B Targets attractively valued companies using strong scientific rationale as the basis for all investment decisions. Share Class Benchmark MSCI World Healthcare Index (Total Return Net) Benchmark uses and resemblance B Performance comparison. The Sub-Fund is actively managed. Though the majority of its holdings (excluding derivatives) are likely to be components of the benchmark, the Investment Manager has broad discretion to deviate from its securities, weightings and risk characteristics. The degree to which the Sub-Fund may resemble the composition and risk characteristics of the benchmark will vary over time and its performance may be meaningfully different. POLICIES Main investment exposure At least 67% of assets invested in Healthcare Companies anywhere in the world. The Sub-Fund may invest in smaller capitalisation companies. Derivatives Used for: efficient portfolio management; hedging. Types: see Sub- Fund Derivatives Usage table under How the Sub-Funds Use Derivatives, Instruments and Techniques in the Prospectus. TRS including CFD: none. Global exposure calculation method: commitment. Currencies Sub-Fund Base Currency: USD. Currencies of asset denomination: any. Hedging approach: typically managed to the currency weights of the benchmark. Redemption and Dealing Shares of the Sub-Fund may be redeemed on demand, with dealing normally on a daily basis. Distribution Policy This Share Class does not pay dividends. Earned income is retained in the NAV. For an explanation of some of the terms used in this document, please visit the glossary on our website at www.jpmorganassetmanagement.lu

Morningstar Rating
More information about the calculation of the Morningstar Ratings
Risk and reward profile
6
Lower Risk
Possible Lower
Returns
Higher Risk
Possible Higher
Returns
Key Information
Closing Price 04/12/2020228.17
Morningstar categorySector Equity Healthcare
CurrencyEUR
Distribution statusAccumulating
ISINLU0880062913
Inception Date01/02/2013
Minimum initial amount500.00 EUR
Fees And Charges
Entry feeNone
Custody feeNone
Exit feeNone
Ongoing charge1.72% of which none is paid to MeDirect
Fund management company
AddressJPMorgan Asset Management (Europe) S.à r.l. European Bank & Business Centre 6, route de Trèves Luxembourg L-2633 Luxembourg
Manager NameAnne Marden
Manager Start Date02/10/2009
Websitehttp://www.jpmorganassetmanagement.com
Total Net Assets (mil)3,147.45 EUR (30/11/2020)
UCITSYes
AdministratorJPMorgan Asset Management (Europe) S.à r.l.

Documents

Prospectus
en 21/10/2020
Annual Report
en 30/06/2020
Semi Annual Report
en 31/12/2019
Morningstar Report
05/12/2020

Performance

Historical returns are no guarantee for future performances. Investing in Financial markets and securities involves risk. Past performance is not a guarantee of future results. Investment losses may occur and investors could lose some or all of their investment in the Fund.
Entry fees, purchase charges, custody fees, exit fees, sale charges and taxes are not included in the calculation of past performance. Ongoing charges (including management fees, administrative fees and other costs) have been taken in to account, as they are already included in the price/NAV of the fund.
Annualised performance in EUR
PeriodAnnualised returnDate
1 year13.55%04/12/2020
3 years13.71%04/12/2020
5 years6.88%04/12/2020
Since launch15.54%04/12/2020
Cumulative performance in EUR
Performance
YTD 01/01/202010.95
1 month-0.98
3 months4.96
6 months5.23
Quarterly Returns
Q 1Q 2Q 3Q 4
2020-8.24%14.34%3.28%-
201910.75%-0.86%0.88%11.68%
2018-5.02%13.15%12.28%-10.91%
20178.22%-1.05%-0.26%-1.09%
2016-16.79%4.98%-0.19%0.06%
Dividend

Asset Allocation
% Long% Short% Net Assets
Stock95.35%0.00%95.35%
Bond0.01%0.00%0.01%
Cash5.25%0.66%4.59%
Other0.04%0.00%0.04%
Return/Risk Analysis
Risk Measurement1 Year3 Years5 Years
Standard Deviation
20.8417.1116.00
Sharpe Ratio
1.010.770.52
Sortino Ratio
2.101.300.79
Positive Months7.0024.0032.00
Negative Months5.0012.0028.00
Worst Month-7.10-9.99-12.63
World Regions
Region%
United States74.77
Europe - ex Euro14.80
United Kingdom3.09
Eurozone0.96
Asia - Emerging0.91
Japan0.82
Stock Sector Weighting
Sector% of Equity
Healthcare93.95
Top 10 Holdings
HoldingSectorCountry% of Assets
UnitedHealth Group Inc HealthcareUnited States6.76
Roche Holding AG Dividend Right Cert. HealthcareSwitzerland4.79
Thermo Fisher Scientific Inc HealthcareUnited States4.64
Johnson & Johnson HealthcareUnited States3.76
Bristol-Myers Squibb Company HealthcareUnited States3.71
Novartis AG HealthcareSwitzerland3.34
Amgen Inc HealthcareUnited States3.14
Eli Lilly and Co HealthcareUnited States2.97
AstraZeneca PLC HealthcareUnited Kingdom2.95
Novo Nordisk A/S B HealthcareDenmark2.78
Classification of Morningstar Category
Ranking1 Year2 Years3 Years5 Years
Top 25%
Category above the average
Category below the average
Bottom 25%
Morningstar Style Box
Equity Style
Large
Size
Mid
Small
Value
Blend
Growth
Style
228.17
Closing Price
All key information and documents must be reviewed before being able to Invest.